CN117224552A - Application of ecliptin in preparation of medicine for treating cerebral ischemia reperfusion injury - Google Patents
Application of ecliptin in preparation of medicine for treating cerebral ischemia reperfusion injury Download PDFInfo
- Publication number
- CN117224552A CN117224552A CN202311267631.5A CN202311267631A CN117224552A CN 117224552 A CN117224552 A CN 117224552A CN 202311267631 A CN202311267631 A CN 202311267631A CN 117224552 A CN117224552 A CN 117224552A
- Authority
- CN
- China
- Prior art keywords
- ecliptin
- cerebral
- mice
- cerebral ischemia
- ischemia reperfusion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010008118 cerebral infarction Diseases 0.000 title claims abstract description 37
- 201000006474 Brain Ischemia Diseases 0.000 title claims abstract description 27
- 206010008120 Cerebral ischaemia Diseases 0.000 title claims abstract description 26
- 206010063837 Reperfusion injury Diseases 0.000 title claims abstract description 20
- 239000003814 drug Substances 0.000 title claims abstract description 13
- 238000002360 preparation method Methods 0.000 title description 3
- 241000699670 Mus sp. Species 0.000 claims abstract description 38
- 230000003727 cerebral blood flow Effects 0.000 claims abstract description 17
- 208000026106 cerebrovascular disease Diseases 0.000 claims abstract description 15
- 210000005036 nerve Anatomy 0.000 claims abstract description 7
- 230000004064 dysfunction Effects 0.000 claims abstract description 4
- 241000699666 Mus <mouse, genus> Species 0.000 abstract description 10
- 238000010171 animal model Methods 0.000 abstract description 6
- 230000010410 reperfusion Effects 0.000 abstract description 5
- 206010008089 Cerebral artery occlusion Diseases 0.000 abstract description 3
- 230000003542 behavioural effect Effects 0.000 abstract description 3
- 201000007309 middle cerebral artery infarction Diseases 0.000 abstract description 3
- 208000005189 Embolism Diseases 0.000 abstract description 2
- 210000001367 artery Anatomy 0.000 abstract description 2
- 210000000133 brain stem Anatomy 0.000 abstract description 2
- 208000006011 Stroke Diseases 0.000 description 9
- 230000017531 blood circulation Effects 0.000 description 7
- 210000004556 brain Anatomy 0.000 description 6
- 230000000302 ischemic effect Effects 0.000 description 5
- PKDBCJSWQUOKDO-UHFFFAOYSA-M 2,3,5-triphenyltetrazolium chloride Chemical compound [Cl-].C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 PKDBCJSWQUOKDO-UHFFFAOYSA-M 0.000 description 4
- 206010008190 Cerebrovascular accident Diseases 0.000 description 4
- 230000002490 cerebral effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000003657 middle cerebral artery Anatomy 0.000 description 4
- 230000008506 pathogenesis Effects 0.000 description 4
- 235000009161 Espostoa lanata Nutrition 0.000 description 3
- 240000001624 Espostoa lanata Species 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000000269 carotid artery external Anatomy 0.000 description 3
- 210000004004 carotid artery internal Anatomy 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- 150000002338 glycosides Chemical class 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 244000286838 Eclipta prostrata Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000032382 Ischaemic stroke Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 210000001168 carotid artery common Anatomy 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 230000009251 neurologic dysfunction Effects 0.000 description 2
- 208000015015 neurological dysfunction Diseases 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000001292 preischemic effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000013077 scoring method Methods 0.000 description 2
- 229960000187 tissue plasminogen activator Drugs 0.000 description 2
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000037823 Cerebral ischemia/reperfusion injury Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000001964 calcium overload Effects 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002461 excitatory amino acid Effects 0.000 description 1
- 239000003257 excitatory amino acid Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000003188 neurobehavioral effect Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 239000004090 neuroprotective agent Substances 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002633 protecting effect Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 229960004380 tramadol Drugs 0.000 description 1
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 1
- 150000008130 triterpenoid saponins Chemical class 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the technical field of cerebrovascular diseases, and relates to an application of ecliptin in preparing a medicament for treating cerebral ischemia reperfusion injury, wherein a cerebral ischemia reperfusion animal model is established through a mouse middle artery embolism model (Middle cerebral artery occlusion, MCAO), and behavioural, dead brain stem volume and cerebral blood flow are observed; compared with the model group, the cerebral infarction volume of the mice in the experimental group is obviously reduced, the nerve function is obviously improved, and the cerebral blood flow is obviously improved, which shows that the ecliptin can obviously reduce the cerebral ischemia reperfusion injury of the mice and improve the nerve dysfunction after cerebral ischemia.
Description
Technical field:
the invention belongs to the technical field of cerebrovascular diseases, and relates to application of ecliptin in preparation of a medicament for treating cerebral ischemia reperfusion injury.
The background technology is as follows:
ischemic stroke is one of the most disabling and deadly diseases among cerebrovascular diseases, with varying degrees of neurological dysfunction accompanying 80% of stroke patients. The pathogenesis of ischemic cerebral apoplexy mainly relates to a plurality of links such as excitatory amino acid toxicity, free radical generation, calcium overload, energy metabolism disorder, inflammation, nerve cell apoptosis and the like, the exact pathogenesis is not clear, and great difficulty is brought to clinical treatment and new medicine research of the ischemic cerebral apoplexy. Currently, treatment of stroke is focused mainly on reducing neuronal cell death. Although this approach has been validated in experimental stroke studies, clinical trials have shown that none of the neuroprotective drugs tested have achieved effective clinical efficacy in the treatment of acute stroke. Recombinant tissue plasminogen activator (recombinant tissue plasminogen activator, rt-PA) is the only drug approved by the U.S. food and drug administration (food and drug administration, FDA) for the treatment of ischemic stroke. However, due to the narrow therapeutic window (< 4.5 h) and the resulting adverse effects of bleeding risk, only 5% of stroke patients currently benefit from rt-PA treatment, and the current state of clinical treatment is not optimistic. Therefore, the method has important significance in solving the clinical problems of unclear exact pathogenesis and insufficient effective intervention means, analyzing the pathogenesis of the ischemic cerebral apoplexy, exploring and developing innovative medicaments with clinical application prospect and relieving clinical dilemma faced by the treatment of the ischemic cerebral apoplexy.
The ecliptin is an effective component of triterpenoid saponins extracted from eclipta, and has liver protecting, immunoregulatory, antioxidant and enzyme activating effects. Wang Aimei it is found that eclipta alba can improve learning and memory functions of AD model rats by reducing neuronal cell loss and improving neurotransmitter metabolism in the hippocampus. At present, research reports on the use of ecliptin for treating cerebral ischemia reperfusion injury are not found yet.
The invention comprises the following steps:
the invention aims to overcome the defects in the prior art and provides an application of ecliptin in preparing a medicament for treating cerebral ischemia reperfusion injury.
In order to achieve the above purpose, the invention provides an application of ecliptin in preparing a medicament for treating cerebral ischemia reperfusion injury, wherein a cerebral ischemia reperfusion animal model is established through a mouse middle artery embolism model (Middle cerebral artery occlusion, MCAO), and behavioural, dead brain stem volume and cerebral blood flow are observed; compared with the model group, the cerebral infarction volume of the mice in the experimental group is obviously reduced, the nerve function is obviously improved, and the cerebral blood flow is obviously improved, which shows that the ecliptin can obviously reduce the cerebral ischemia reperfusion injury of the mice and improve the nerve dysfunction after cerebral ischemia.
The ecliptin is ecliptin total glycoside and is purchased from Nanjing Puyi biotechnology Co.
Compared with the prior art, the invention uses the ecliptin for treating cerebral ischemia reperfusion injury for the first time, can obviously reduce cerebral infarction volume, promote cerebral blood flow and improve nerve dysfunction after cerebral ischemia, which shows that the ecliptin can be used for improving cerebral ischemia reperfusion injury and provides experimental data and theoretical basis for developing the use of the ecliptin for treating cerebrovascular diseases.
Description of the drawings:
fig. 1 is a schematic diagram of experimental results of influence of ecliptin on cerebral ischemia reperfusion injury mice cerebral blood flow, wherein a is a laser doppler flow chart, and B is a cerebral blood flow histogram.
FIG. 2 is a schematic representation of experimental results of the effect of ecliptin according to the present invention on the behavioral score of mice with cerebral ischemia reperfusion injury, wherein # represents p <0.01 compared to Sham group and x represents p <0.01 compared to MCAO/R group.
Fig. 3 is a schematic diagram of experimental results of influence of ecliptin on cerebral ischemia reperfusion injury mice cerebral infarction volume, wherein A is a TTC stained brain slice diagram, and B is a cerebral infarction volume histogram.
The specific embodiment is as follows:
the invention will now be described in further detail with reference to the following examples in conjunction with the accompanying drawings.
Example 1.
The embodiment relates to an experiment for influencing the cerebral ischemia reperfusion injury cerebral infarction volume of mice by ecliptin, which comprises the following steps:
(1) Experimental animals: healthy male C57 mice, 23 g-25 g, are provided by Jinan Pengyue laboratory animal breeding Limited company, purchased 1 week before the experiment, placed in SPF-class animal laboratory at the temperature (25-27) DEG C, and fed with water.
(2) Experimental medicine: ecliptae herba glycoside is purchased from Nanjing Proyi biotechnology Co., ltd; when in use, a certain amount of ecliptin is weighed, prepared by normal saline, and fully dissolved by ultrasonic waves at 37 ℃.
(3) Construction of MCAO/R mouse brain ischemia reperfusion injury animal model
1) Mice were randomly divided into 3 groups, one group was Sham surgery (Sham) group, 6 groups was model (6) group, and one group was model+dosing group (19). Model group and model + dosing group a model of focal cerebral ischemia/reperfusion injury in mice was prepared using middle cerebral artery occlusion surgery. Before operation, selecting a bolt line with a corresponding model according to the weight of the mouse, and blackening the non-spherical end of the bolt line by using a black waterproof marker pen so as to be convenient for searching the bolt line during later bolt line pulling. Mouse intraperitoneal injection of ketamine (80 mg kg) -1 ) And tolylthiazide (10 mg.kg) -1 ) Anesthesia. The mouse is fixed on a mouse operating table in a supine position, the alcohol cotton ball disinfects the neck, and the skin is cut off by surgical scissors in the middle of the neck. The forceps delaminate the tissue layer by layer, separating the left Common Carotid Artery (CCA), the External Carotid Artery (ECA), and the Internal Carotid Artery (ICA) in sequence. Cutting a wedge-shaped small opening at the ECA, inserting an MCAO model bolt line, and lightly pushing the bolt line to enter the internal carotid artery until the bolt line is inserted into the Middle Cerebral Artery (MCA) starting point to cause the blood flow supply disorder of the MCA; after ischemia for 2 hours, slowly pulling out the thrombus line to carry out blood flow reperfusion for 22 hours; iodophor disinfection, aseptic surgical suture wound suturing, tail vein tramadol (2.5 mg kg) -1 ) To reduce postoperative pain. Sham mice used the same surgical procedure described above, but did not block MCA. All post-operative experimental animals were placed on a heating pad to maintain body temperature at 37±0.5 ℃ until the mice wake up.
2) Laser Doppler blood flow monitor for monitoring cerebral blood flow of mice
Whether the cerebral ischemia reperfusion injury model is successful or not is usually monitored by using a laser Doppler blood flow instrument for the cerebral blood flow change of the mice. The specific operation is as follows: placing the anesthetized mice in a tray, sterilizing hair and skin at the top of the heads of the mice by alcohol, cutting off the skin at the top of the heads of the mice by surgical scissors, cleaning the hair remained at the cutting-off position of the heads by cotton balls dipped with physiological saline, and observing cerebral blood flow under the cameras of a laser Doppler blood flow instrument at the heads of the mice. The evaluation criteria are: the mice were considered successful in terms of cerebral blood flow that fell below 40-30% of pre-ischemic.
(3) Randomly dividing the model after modeling and the mice of the administration group into 3 groups, wherein 6-7 mice in each group are respectively a low dose group, a medium dose group and a high dose group of ecliptin, wherein the low dose group of ecliptin (ES 12.5 mg/kg), and after modeling, each mouse is administered with 12.5mg of ecliptin per kilogram of body weight and is continuously administered by gastric lavage for 7 days; dose group of ecliptin (ES 25 mg/kg), after molding, 25mg of ecliptin was administered per kg body weight per mouse, followed by gastric lavage for 7 days; ecliptin high dose group (ES 50 mg/kg), after molding, 50mg of ecliptin was administered per kg body weight per mouse, followed by gastric lavage for 7 days. The model group was not subjected to drug administration treatment after molding.
(4) Effect of ecliptin on cerebral blood flow in MCAO/R mice
After 7 days of administration, each group of mice was anesthetized, placed in a tray, the top skin of the mice was cut by surgical scissors, the hair remaining at the head-cut position was cleaned with a cotton ball dipped with physiological saline, and the heads of the mice were photographed under a laser Doppler blood flow meter camera to observe blood flow. The results are shown in FIG. 1.
As can be seen from FIG. 1, the model group (MCAO/R) mice had significantly reduced cerebral blood flow to 40-30% of pre-ischemic compared to the Sham group, and the modeling was considered successful. Further observing the change of different doses of ecliptin on cerebral blood flow, the result shows that the ecliptin can obviously increase the cerebral blood flow of mice in 7 days after medium-dose and high-dose treatment administration, thus indicating that the ecliptin plays a key role in restoring cerebral blood flow of mice.
(5) Influence of Ecliptae herba glycoside on cerebral ischemia reperfusion nerve function injury of mice
All mice were scored neuro-behaviourally 7 days after dosing according to Longa scale 5 scoring method, the results are shown in figure 2.
Table 1Longa class 5 scoring method
As can be seen from fig. 2, the mice in the medium and high dose ecliptin groups have lower neurobehavioral scores compared to the model group, indicating that administration of the medium and high dose ecliptin for 7 days can significantly reduce the neurological scores and improve the neurological dysfunction of the mice. Figure 2 is counted using a one-way anova, # represents p <0.01 compared to Sham group and x represents p <0.01 compared to MCAO/R group.
(6) Influence of ecliptin on cerebral ischemia reperfusion injury cerebral infarction volume of mice
After 7 days of administration, mice were sacrificed and brain tissue was removed and immediately placed in a-80 ℃ freezer. Placing 2% TTC (2, 3, 5-triphenyltetrazolium chloride) aqueous solution in a 37 ℃ incubator, preheating for 15min in advance, and cutting frozen brain tissue into 6 slices with the thickness of 2mm; sequentially placing the cut brain slices into TTC preheated by a incubator at 37 ℃ for shading and dyeing for 15min; and (3) putting the dyed brain slices into 4% paraformaldehyde for fixation overnight, and sequentially arranging the fixed brain slices on black background filter paper and taking pictures by a digital camera. Cerebral infarction volume= (sum of ischemic side areas)/(sum of whole brain areas) ×brain sheet thickness×100%. The results are shown in FIG. 3.
As can be seen from fig. 3, compared with the model group, the treatment administration of the ecliptin in the medium-dose group and the high-dose group for 7 days can obviously reduce the cerebral infarction volume caused by ischemia reperfusion of the mice, which indicates that the ecliptin has obvious improvement effect on the cerebral infarction volume of the mice.
Claims (1)
1. The application of ecliptin in preparing a medicament for treating cerebral ischemia reperfusion injury is characterized in that ecliptin can obviously reduce cerebral ischemia reperfusion injury of mice, reduce cerebral infarction volume, promote cerebral blood flow and improve nerve dysfunction after cerebral ischemia.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311267631.5A CN117224552A (en) | 2023-09-28 | 2023-09-28 | Application of ecliptin in preparation of medicine for treating cerebral ischemia reperfusion injury |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311267631.5A CN117224552A (en) | 2023-09-28 | 2023-09-28 | Application of ecliptin in preparation of medicine for treating cerebral ischemia reperfusion injury |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117224552A true CN117224552A (en) | 2023-12-15 |
Family
ID=89090921
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311267631.5A Pending CN117224552A (en) | 2023-09-28 | 2023-09-28 | Application of ecliptin in preparation of medicine for treating cerebral ischemia reperfusion injury |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117224552A (en) |
-
2023
- 2023-09-28 CN CN202311267631.5A patent/CN117224552A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Richardson | Diseases of domestic guinea pigs | |
| AT504159A1 (en) | USE OF PROTEASES | |
| CN115317484B (en) | Application of LY2922470 in preparing medicine for preventing or treating cerebrovascular diseases or tissue ischemia reperfusion injury | |
| CN106604724A (en) | Composition for reducing local fat and body weight, and pharmaceuticals and use thereof | |
| STAGE | Severe burns in the pregnant patient | |
| CN117224552A (en) | Application of ecliptin in preparation of medicine for treating cerebral ischemia reperfusion injury | |
| CN111450089A (en) | Application of Bepridil or KB-R7943 in preparation of medicine for treating melanoma | |
| WO2021051260A1 (en) | Traditional chinese medicine composition for treating traumatic injury and use thereof | |
| Curtis et al. | Canine eosinophilic folliculitis and furunculosis in three cases | |
| Cui et al. | Prophylactic strategy with herbal remedy to reduce puerperal metritis risk in dairy cows: A randomized clinical trial | |
| CN117243949A (en) | Application of wedelolactone in preparation of medicine for treating cerebral ischemia reperfusion injury | |
| CN113813270A (en) | Medicament for preventing and/or treating skin fibrosis | |
| US20150352171A1 (en) | Herpes Treatment | |
| RU2751034C1 (en) | Method of production of a preparation for treatment of bovine endometritis | |
| CN109674774B (en) | Application of propane-1-alcohol compound in preparation of medicine for treating cerebral hemorrhage | |
| RU2744919C1 (en) | Remedy for the treatment of endometritis in cows | |
| CN104825478B (en) | A kind of preparation method for being used to treat the pharmaceutical composition and its perfusion liquid of cow endometritis | |
| Şengül et al. | Effect of royal jelly on puberty of ewe lambs. | |
| Muthie | Late Eyelid Reconstruction of Necrotizing Fasciitis | |
| Nigar et al. | Effects of Medroxy Progesterone Acetate (Inject-Able Contraceptive) on Diameter of Graffian Follicle (Ovary) of Adult Albino Rats | |
| RU2528916C1 (en) | Method of comprehensive treatment of cows with postpartum endometritis | |
| Das et al. | CTVT INDUCED UNUSUAL SWELLING OF PENILE REGION OF A DOG AND ITS THERAPEUTIC MANAGEMENT | |
| CN117138019A (en) | Composition for treating onychomycosis as well as preparation method and application thereof | |
| Ramey et al. | The influence of pentoxifylline (Trental) on the antifertility effect of intrauterine devices in rats | |
| Ali et al. | Healing Rate of Ruminal Incision in Sheep After Single Dose Effect of Low Level Laser Therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |